U.S. market projected to hit USD 8.82 Billion by 2035, while Europe market is expected to reach USD 8.92 Billion driven by expanding women’s health initiatives and HRT adoption.
Austin, United States, May 21, 2026 (GLOBE NEWSWIRE) — “According to SNS Insider, the global Menopause Treatment Market was valued at USD 18.81 Billion in 2025 and is projected to reach USD 31.95 Billion by 2035, expanding at a CAGR of 5.44% during 2026–2035.”
The market growth is fueled by shifting societal perception towards menopause, enhanced access to healthcare, and the development of innovative pharmaceutical products aimed at improving the lives of menopausal women. Growing demand for tailored menopause care, telemedicine-based solutions, and natural remedies also contributes to further market expansion in the long term.
Menopause Treatment Market Size & Forecast
- Market Size (2025): USD 18.81 Billion
- Projected Market Size (2035): USD 31.95 Billion
- CAGR (2026–2035): 5.44%
- Forecast Period: 2026–2035
- Base Year: 2025
Get a Sample Report of Menopause Treatment Market Forecast @ https://www.snsinsider.com/sample-request/8106
The U.S. Menopause Treatment Market is projected to grow from USD 5.60 Billion in 2025 to USD 8.82 Billion by 2035, at a CAGR of 4.63%.
Increasing number of women who have entered menopause every year, growing need for novel menopausal symptoms therapies, and rapid expansion of specialized healthcare services significantly fueled the development of the U.S. menopause treatment market. Launch of novel non-hormonal pharmaceuticals such as Veozah, increased penetration of insurance policies and menopause-friendly company benefits, as well as greater awareness of menopause-related conditions, are expected to fuel further market growth in the coming years.
The Europe Menopause Treatment Market is estimated to be USD 5.46 Billion in 2025 and is projected to reach USD 8.92 Billion by 2035, growing at a CAGR of 5.03% during 2026–2035.
Europe is an advanced market for treatments during menopause, due to the NICE guidelines in the UK that suggest hormonal replacement therapy (HRT) for suitable patients, as well as the well-developed healthcare system in Germany allowing hormonal therapy treatments, and the advocacy for women’s health issues in Scandinavia.
Rising Growth of the Unprecedented Menopausal Population to Boost Market Growth Globally
Structural Growth Drivers of the Menopause Treatment Market include the unparalleled growth in the size of the worldwide menopausal population, expected to number 1.2 billion women by 2030, forming the largest patient pool in history, alongside an unprecedented innovation cycle for drug development within the sector, which involves developing new treatments beyond HRT, including new technologies and personalized therapies using bioidentical hormones.
Leading Market Players Listed in this Report are:
- Pfizer Inc.
- Bayer AG
- AbbVie Inc.
- Organon and Co.
- Amneal Pharmaceuticals LLC
- Novo Nordisk AS
- Teva Pharmaceutical Industries Ltd.
- Theramex SAS
- Hisamitsu Pharmaceutical Co. Inc.
- Besins Healthcare
- Shionogi and Co. Ltd.
- TherapeuticsMD Inc.
- Astellia (Mithra Pharmaceuticals SA)
- Gedeon Richter plc
- Procter and Gamble Co.
- Nature’s Way Products LLC
- Metagenics Inc.
- Garden of Life LLC
- Solgar Inc.
- Standard Process Inc.
Segmentation Analysis:
By Treatment Type
Dietary Supplements and Herbal Remedies occupied the leading position and had the maximum share of the market in 2025 since they cater to the needs of consumers who prefer natural and easily available products for alleviating the symptoms of menopause. Non-Hormonal Therapies were the segments that recorded rapid growth due to the introduction of new therapies that use NK3 receptor antagonists and the adoption of SSRI and SNRI drugs for managing vasomotor symptoms.
By Mode of Administration
Oral was the leading mode of administration that dominated the market as it involved easy administration and availability of medicines and supplements. Topical and Transdermal occupied second place in terms of growth due to the increase in preference for products that deliver hormones without undergoing first-pass metabolism and have safe cardiovascular profiles.
By Indication
Menopause had the maximum revenue share since women prefer seeking medical treatment for their symptoms at this stage of the process. Postmenopause is anticipated to be a lucrative segment in the coming years owing to the increasing requirement for addressing bone health, cardiovascular conditions, and genitourinary syndromes in women.
By Distribution Channel
However, Drug Stores and Retail Pharmacies had the highest revenue share, about 42%, in 2025 owing to their trusted brand reputation, availability of multiple product types, and easy access. Online Pharmacies accounted for the fastest-growing distribution channel on account of an increasing number of telehealth-based prescription services, e-commerce-based sales of supplements, and menopause care platforms targeting consumers directly.
Do you have any specific queries or need any customized research on Menopause Treatment Market? Schedule a Call with Our Analyst Team @ https://www.snsinsider.com/enquiry/8106
Regional Analysis:
North America was the leading regional market in the Menopause Treatment Market in 2025 with the largest revenue share owing to its excellent healthcare infrastructure and higher awareness among consumers about the importance of managing menopause along with availability of many approved pharmaceutical therapies. Moreover, the growing usage of non-hormonal therapies for menopause and investments made by large pharmaceutical companies in research and development of new therapies for women’s diseases in the region further boosted the growth of the market.
Asia-Pacific was expected to show the fastest regional growth rate during the forecast period owing to rapidly aging female population, increasing healthcare awareness among females, and greater availability of healthcare facilities for treating women-specific diseases in regions such as Japan, China, India, and South Korea.
Recent Developments:
- In October 2024, Bayer received U.S. FDA acceptance for its New Drug Application for elinzanetant, an NK3 receptor antagonist developed for moderate to severe vasomotor symptoms associated with menopause, supported by positive Phase III OASIS trial results.
- In 2025, Pfizer expanded insurance coverage and patient support initiatives for Veozah, the first FDA-approved non-hormonal NK3 receptor antagonist for menopause-related vasomotor symptoms, strengthening commercial accessibility across the United States.
Exclusive Sections of the Report (The USPs):
- TREATMENT ADOPTION TREND ANALYSIS – helps you understand changing patient preferences toward hormonal, non-hormonal, and supplement-based menopause therapies across global markets.
- MENOPAUSAL POPULATION FORECAST INSIGHTS – helps you evaluate long-term demand potential based on aging female demographics and rising treatment-seeking behavior globally.
- NON-HORMONAL THERAPY PIPELINE ASSESSMENT – helps you identify upcoming pharmaceutical innovations, clinical trial progress, and future commercialization opportunities in menopause care.
- DIGITAL MENOPAUSE CARE PLATFORM ANALYSIS – helps you assess the growing role of telehealth services, menopause apps, and digital treatment management platforms in improving patient engagement.
- REGIONAL ACCESSIBILITY & AWARENESS COMPARISON – helps you uncover differences in healthcare infrastructure, menopause awareness, and treatment penetration rates across developed and emerging regions.
- REIMBURSEMENT & INSURANCE COVERAGE INSIGHTS – helps you understand how evolving insurance policies, employer healthcare programs, and reimbursement pathways are influencing treatment accessibility worldwide.
Purchase Single User PDF of Menopause Treatment Market Report (20% Discount) @ https://www.snsinsider.com/checkout/8106
Menopause Treatment Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 18.81 Billion |
| Market Size by 2035 | USD 31.95 Billion |
| CAGR | CAGR of 5.44% From 2026 to 2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Historical Data | 2022-2024 |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Related Market Reports
Hormone Replacement Therapy Market Size, Share & Growth Report 2026
Women’s Healthcare Market Trends, Outlook & Analysis 2026
Women’s Health and Beauty Supplements Market Growth & Demand 2026
Women’s Health Diagnostics Market Size & Forecast 2026
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315-961-9094 (US) Email: [email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaChron.com takes no editorial responsibility for the same.